A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

July 14, 2023

Study Completion Date

October 17, 2023

Conditions
Familial Chylomicronemia Syndrome
Interventions
DRUG

Olezarsen

Olezarsen was administered by SC injection.

DRUG

Placebo

Olezarsen-matching placebo was administered by SC injection.

Trial Locations (47)

10016

New York University (NYU) Langone Medical Center, New York

10032

Columbia University Medical Center, New York

13385

Assistance Publique - Hopitaux de Marseille, Marseille

15001

Hospital Abente y Lago, A Coruña

19104

University of Pennsylvania, Philadelphia

20162

ASST Grande Ospedale Metropolitano Niguarda, Milan

21000

CHU Dijon - Bocage, Dijon

23510

York Clinical Research LLC, Norfolk

26506

West Virginia University Heart and Vascular Institute, Morgantown

27401

Moses H. Cone Memorial Hospital, Greensboro

28041

Hospital Universitario 12 de Octubre, Madrid

33434

Excel Medical Clinical Trials, LLC, Boca Raton

37232

Vanderbilt University, Nashville

41013

Hospital Universitario Virgen del Rocio, Seville

43204

Fundacio Pere Virgili, Tarragona

46290

Ascension St. Vincent Cardiovascular Research Institute, Indianapolis

48105

University of Michigan- Endocrinology & Metabolism, Ann Arbor

60068

Advocate Health and Hospitals Corporation - Lutheran General Hospital, Park Ridge

60201

NorthShore University Health System, Evanston

66160

University of Kansas Medical Center (KUMC), Kansas City

69677

Hôpital Louis Pradel - HCL, Bron

75390

University of Texas Southwestern, Dallas

77030

Baylor College of Medicine, Houston

80131

Azienda Ospedaliera Universitaria Federico II, Napoli

83301

Metabolicke centrum MUDr Katariny Raslovej s. r. o., Bratislava

90127

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo

92648

Diabetes/Lipid Management & Research Center, Huntington Beach

94143

University of California, San Francisco (UCSF) - Medical Center, San Francisco

G7H 7K9

Ecogene-21, Chicoutimi

H2W 1R7

Nathalie Saint-Pierre, Montreal

Institute de Recherches Cliniques de Montreal, Montreal

G1V 4W2

Clinique des Maladies Lipidiques de Quebec Inc., Québec

00161

Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma

1105 AZ

Academic Medical Center - Department of Vascular Medicine, Amsterdam

3015 GD

Erasmus MC, Rotterdam

3584 CX

Universitair Medisch Centrum Utrecht, Utrecht

0372

The Lipid Clinic (Oslo University Hospital), Oslo

2790-134

Centro Hospitalar de Lisboa Ocidental. E.P.E, - Hospital Santa Cruz, Carnaxide

4835-044

Hospital da Senhora da Oliveira - Guimaraes, Creixomil

1349-019

Centro Hospitalar de Lisboa Ocidental, EPE - Hospital Egas Moniz, Lisbon

08036

Hospital Clinic Barcelona, Barcelona

413 45

Sahlgrenska University Hospital, Gothenburg

171 76

Karolinska University Hospital, Solna

NW3 2QG

The Royal Free Hospital, London

SE1 7EH

St. Thomas' Hospital, London

MI39WL

Manchester University NHS Foundation Trust (MFT), Manchester

B71 4HJ

Sandwell General Hospital, West Bromwich

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY